Supn stock zacks

Jan 01, 2010 · Trade SUPN stock with recommended broker Ally Invest. Commissions as low as $3.95. (SUPN) Q2 Earnings Top Estimates Zacks Aug 06, 2019 Benzinga is a … 3 Undervalued Stocks That Should Gain Ground in 2020 ... Jan 24, 2020 · 3 Undervalued Stocks That Should Gain Ground in 2020 American Airlines, Supernus Pharmaceuticals and TPI Composites should see their fortunes improve this year.

Corcept: A Profitable Biotech Stock. Corcept Therapeutics (CORT) is ranked No. 12 out of 150 fastest-growing stocks noted by MarketSmith. Over the past five  Supernus Pharmaceuticals, Inc. - SUPN - Stock Price Today ... View Supernus Pharmaceuticals, Inc. SUPN investment & stock information. Get the latest Supernus Pharmaceuticals, Inc. SUPN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis ... Get breaking news and analysis on Supernus Pharmaceuticals, Inc. (SUPN) stock, price quote and chart, trading and investing tools.

The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. For the SUPN price target at the top of this page, we present the average SUPN target price across the 5 analysts covering SUPN, as reported in data provided by Zacks …

Wall Street brokerages expect Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to report earnings of $0.57 per share for the current quarter, according to Zacks. Four analysts have made estimates for Supernus Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $0.56 and the highest estimate coming in at $0.59. Supernus Pharmaceuticals reported earnings per share of […] SUPN Earnings Date, Forecast and Report (Supernus ... Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more. Zacks Investment Research Upgrades Supernus ... Zacks Investment Research upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a strong sell rating to a hold rating in a research note published on Thursday morning, Zacks.com reports.. According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases.

Supernus (SUPN) delivered earnings and revenue surprises of 8.77% and -6.36%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock? Tue, Jan 21, 8:40 AM, Zacks Can Value Investors Pick Supernus Pharmaceuticals (SUPN) Stock?

investment & stock information. Get the latest Supernus Pharmaceuticals, Inc. SUPN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of A. Style Scorecard. SUPN: Supernus Pharmaceuticals, Inc. - Earnings Announcements. Stay up to date Zacks Rank: 3-Hold 3 View All Zacks #1 Ranked Stocks. Trades from $1 . 25 Feb 2020 Supernus (SUPN) delivered earnings and revenue surprises of 8.77% and -6.36 %, Do the numbers hold clues to what lies ahead for the stock? 21 Jan 2020 Can Value Investors Pick Supernus Pharmaceuticals (SUPN) Stock? Zacks Equity Research January 21, 2020. SUPN. Trades from $1. 25 Feb 2020 Supernus (SUPN) delivered earnings and revenue surprises of 8.77% the current status translates into a Zacks Rank #3 (Hold) for the stock.

8 Mar 2020 4 Insurance Stocks for Your Investment Portfolio in 2020. Zacks CHK, FCEL, SUPN and PAYS among midday movers. SeekingAlpha 

View Akorn, Inc.'s fair value, stock price, financial statements, news, valuation The Zacks Analyst Blog Highlights: Forterra, Barrett Business, Chuy's,  24 Feb 2020 Zacks Investment Research upgraded Supernus Pharmaceuticals from Six equities research analysts have rated the stock with a hold rating  Corcept: A Profitable Biotech Stock. Corcept Therapeutics (CORT) is ranked No. 12 out of 150 fastest-growing stocks noted by MarketSmith. Over the past five  Supernus Pharmaceuticals, Inc. - SUPN - Stock Price Today ... View Supernus Pharmaceuticals, Inc. SUPN investment & stock information. Get the latest Supernus Pharmaceuticals, Inc. SUPN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis ...

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.48 per share a year ago.

ROCKVILLE, Md. (AP) _ Supernus Pharmaceuticals Inc. (SUPN) on Tuesday reported second-quarter net income of $32.7 million. On a per-share basis, the Rockville, Maryland-based company said it had profit of 61 cents.. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of 56 cents per share. ETFs Holding SUPN | Supernus Pharmaceuticals Inc | ETF Channel SUPN Description — Supernus Pharmaceuticals Inc. Supernus Pharmaceuticals is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. Co. has launched Oxtellar XR and Trokendi XR, its two treatments for epilepsy.

Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more. Zacks Investment Research Upgrades Supernus ... Zacks Investment Research upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a strong sell rating to a hold rating in a research note published on Thursday morning, Zacks.com reports.. According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. Supernus Pharmaceuticals News | Markets Insider